Royalty Pharma (NASDAQ:RPRX) Price Target Raised to $62.00

Дата публикации: 10-08-2026 05:48:47

Royalty Pharma (NASDAQ:RPRX – Free Report) had its price target boosted by JPMorgan Chase & Co. from $58.00 to $62.00 in a research note published on Friday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. Several other research analysts also recently commented on the company. Wall Street Zen upgraded Royalty Pharma […]

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Replimune Group (NASDAQ:REPL) Price Target Raised to $20.00	0	13.83	10-08-2026
2	Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $146.00	0	14.22	10-08-2026
3	Odyssey Therapeutics (NASDAQ:ODTX) Price Target Raised to $29.00	0	14.24	10-08-2026
4	Target (NYSE:TGT) Price Target Raised to $157.00	0	13.85	10-08-2026
5	Roivant Sciences (NASDAQ:ROIV) Price Target Raised to $42.00	0	11.84	10-08-2026
6	Maplebear (NASDAQ:CART) Price Target Raised to $62.00	0	13.46	10-08-2026
7	Qiagen (NYSE:QGEN) Price Target Raised to $50.00	0	14.26	10-08-2026
8	PAR Technology (NYSE:PAR) Price Target Raised to $18.00	0	14.24	10-08-2026
9	Celldex Therapeutics (NASDAQ:CLDX) Price Target Raised to $53.00	0	11.84	10-08-2026
10	Genpact (NYSE:G) Price Target Raised to $45.00	0	14.26	10-08-2026

Классификация: Экономика. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 13.82. Источник: www.americanbankingnews.com.